MEIM secures tens of millions in Series A to advance next-gen vascular ablation systems

Micro-Energy Medical Technology (MEIM) recently announced the completion of a tens of millions of RMB Series A financing round. This round was led by Lotus Lake Capital, with participation from existing investor Taiyu Capital. Hanyu Capital continued to serve as the exclusive financial advisor.

This marks another significant capital infusion for MEIM, following an angel round from Puhua Capital in 2023 and a Pre-A round from Taiyu Capital, Guochuang Qianzhi Capital, and Huagai Capital in 2024. This latest financing reflects the market's positive response to and high expectations for the high-end medical industry. It is poised to inject strong momentum into the company's product development, clinical application, and global expansion, aiding its breakthrough in innovation.

Founded in 2021, MEIM has been dedicated to addressing clinical pain points in vascular diseases, focusing deeply on the promising field of active energy-based vascular intervention. Since its inception, MEIM has leveraged industry advantages and pooled expertise from China and Germany. It has established production bases and R&D offices in Hangzhou, Shenzhen, and Coburg, Germany, building a global operational network. The founding team possesses years of industry experience, unique international vision, and a clear strategic development plan. The Chinese team, comprising veterans from leading companies like OrbusNeich, Mindray, and EDAN Instruments, as well as top-tier research institutions such as Tsinghua University, Peking Union Medical College, and The Chinese University of Hong Kong, brings profound multidisciplinary R&D expertise. Coupled with top-tier international experts from Germany's laser field, this powerful alliance provides solid support for technological innovation.

Regarding its product portfolio, MEIM focuses on addressing critical clinical needs, aiming to create a "China-first" and "globally-leading" matrix of active energy-based vascular interventional products. This matrix encompasses four core product lines: a 355nm solid-state pulsed laser vascular ablation system, a differentiated innovative shockwave balloon system, a 1470nm & 1940nm laser ablation system, and a Laser Renal Denervation (RDN) system. These products are designed to treat prevalent conditions within the pan-vascular field, including coronary and peripheral arteries and veins, while rapidly expanding into clinical indications across surgical and non-surgical domains.

Currently, the SurgiLight® 1470 system—China's first 1470nm wavelength circumferential fiber endovenous laser ablation (EVLA) system with independent intellectual property rights—has obtained registration certificates both domestically and internationally and has been officially launched to the market, receiving high praise from medical institutions and clinical experts. Other product lines are progressing as planned, with clinical trials steadily advancing.

Simultaneously, MEIM's diverse background and international market positioning, combined with its leading-edge technology and products that face few market substitutes, have generated significant interest and favor from overseas markets in recent years. It is reported that, driven actively by its international sales team, MEIM's products are now undergoing registration and initial sales in major vascular interventional markets such as the United States, Mexico, Brazil, Indonesia, Vietnam, and India. Market deployment is steadily progressing in the European Union, Saudi Arabia, the United Arab Emirates, among others, with sales expected to commence formally in 2026.